Rodriguez 1994.

Methods	Design: multicentre, randomised, double blind, parallel group study Duration: 7 days Setting: Oncology departments in Spain
Participants	Cancer pain, with pre study intensity > 70/100 mm N = 149 eligible, 121 participated 70% men Mean age 61 years Baseline VAS PI > 70/100
Interventions	MIR 10 mg 4‐hourly, increasing to 30 mg 4‐hourly, n = 42 Dipyrone 1 g 8‐hourly, increasing to 2 g 8‐hourly, + placebo to maintain blinding, n = 41 Dipyrone 2 g 8‐hourly, + placebo to maintain blinding, n = 38 No other medication allowed Rescue medication: paracetamol 300 mg and codeine 15 mg
Outcomes	PI: VAS, daily Adverse events: check list ‐ severity judged by investigators
Notes	Oxford Quality Score: R = 1, DB = 1, W = 1. Total = 3/5
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"randomised". Method used to generate sequence not clearly stated
Allocation concealment (selection bias)	Unclear risk	Method not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	"double blind". Method not described
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	"double blind". Method not described
Incomplete adverse event outcome data‐ patient level	Low risk	<90% participants included
Selective reporting bias for adverse events	Unclear risk	All AEs by events appear to be included
Size	High risk	< 50 participants per treatment arm